371 related articles for article (PubMed ID: 26408297)
1. Molecular and clinical implementations of ovarian cancer mouse avatar models.
Zayed AA; Mandrekar SJ; Haluska P
Chin Clin Oncol; 2015 Sep; 4(3):30. PubMed ID: 26408297
[TBL] [Abstract][Full Text] [Related]
2. The future of patient-derived tumor xenografts in cancer treatment.
Sia D; Moeini A; Labgaa I; Villanueva A
Pharmacogenomics; 2015; 16(14):1671-83. PubMed ID: 26402657
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenograft models for personalized medicine in colorectal cancer.
Xie J; Lin Y
Clin Exp Med; 2020 May; 20(2):167-172. PubMed ID: 32100151
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization.
Sun S; Zhang Z
Front Med; 2016 Mar; 10(1):104-10. PubMed ID: 26926009
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer.
Wang Y; Cui J; Wang L
Chin Clin Oncol; 2019 Apr; 8(2):17. PubMed ID: 30943729
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
7. The latest animal models of ovarian cancer for novel drug discovery.
Magnotti E; Marasco WA
Expert Opin Drug Discov; 2018 Mar; 13(3):249-257. PubMed ID: 29338446
[TBL] [Abstract][Full Text] [Related]
8. Current Status of Patient-Derived Ovarian Cancer Models.
Maru Y; Hippo Y
Cells; 2019 May; 8(5):. PubMed ID: 31130643
[TBL] [Abstract][Full Text] [Related]
9. Ovarian and cervical cancer patient derived xenografts: The past, present, and future.
Boone JD; Dobbin ZC; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2015 Aug; 138(2):486-91. PubMed ID: 26026736
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenografts as tools in pharmaceutical development.
Izumchenko E; Meir J; Bedi A; Wysocki PT; Hoque MO; Sidransky D
Clin Pharmacol Ther; 2016 Jun; 99(6):612-21. PubMed ID: 26874468
[TBL] [Abstract][Full Text] [Related]
11. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research.
Jung J; Seol HS; Chang S
Cancer Res Treat; 2018 Jan; 50(1):1-10. PubMed ID: 28903551
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.
Davies AH; Wang Y; Zoubeidi A
Mol Cell Endocrinol; 2018 Feb; 462(Pt A):17-24. PubMed ID: 28315377
[TBL] [Abstract][Full Text] [Related]
13. Prioritizing therapeutic targets using patient-derived xenograft models.
Lodhia KA; Hadley AM; Haluska P; Scott CL
Biochim Biophys Acta; 2015 Apr; 1855(2):223-34. PubMed ID: 25783201
[TBL] [Abstract][Full Text] [Related]
14. Generation of stable PDX derived cell lines using conditional reprogramming.
Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM
Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
16. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
Thorel L; Divoux J; Lequesne J; Babin G; Morice PM; Florent R; Desmartin G; Lecouflet L; Marde Alagama C; Leconte A; Clarisse B; Briand M; Rouzier R; Gaichies L; Martin-Françoise S; Le Brun JF; Denoyelle C; Vigneron N; Jeanne C; Blanc-Fournier C; Leman R; Vaur D; Figeac M; Meryet-Figuiere M; Joly F; Weiswald LB; Poulain L; Dolivet E
BMC Cancer; 2024 Jun; 24(1):701. PubMed ID: 38849726
[TBL] [Abstract][Full Text] [Related]
17. Modeling rectal cancer to advance neoadjuvant precision therapy.
Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived tumor xenograft models for melanoma drug discovery.
Harris AL; Joseph RW; Copland JA
Expert Opin Drug Discov; 2016 Sep; 11(9):895-906. PubMed ID: 27454070
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.
Scott CL; Becker MA; Haluska P; Samimi G
Front Oncol; 2013 Dec; 3():295. PubMed ID: 24363999
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenograft (PDX) models, applications and challenges in cancer research.
Abdolahi S; Ghazvinian Z; Muhammadnejad S; Saleh M; Asadzadeh Aghdaei H; Baghaei K
J Transl Med; 2022 May; 20(1):206. PubMed ID: 35538576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
